

I. PE (n= 97 (4.8%))			GDM		OR	aOR
			-	+		
		Total	67/1465 (4.6%)	30/576 (5.2%)	1.15 (CI 0.74-1.78)	1.18 (CI 0.70-1.97)
Hypertension	-	50/1682 (3.0%)	33/1216 (2.7%)	17/466 (3.6%)	1.36 (CI 0.75-2.46)	1.27 (CI 0.67-2.41)
	+	47/358 (13.1%)	34/249 (13.7%)	13/109 (11.9%)	0.86 (CI 0.43-1.70)	1.20 (CI 0.49-2.93)
	OR	4.93 (CI 3.25-7.48)	5.67 (CI 3.44-9.35)	3.58 (CI 1.68-7.61)		
	aOR	3.14 (CI 1.94-5.10)	3.61 (CI 2.04-6.40)	2.02 (CI 0.79-5.20)		
Obesity	-	69/1416 (4.9%)	54/1103 (4.9%)	15/313 (4.8%)	0.98 (CI 0.54-1.76)	0.96 (CI 0.49-1.89)
	+	28/618 (4.5%)	13/358 (3.6%)	15/260 (5.8%)	1.63 (CI 0.76-3.48)	1.92 (CI 0.80-4.61)
	OR	0.93 (CI 0.59-1.45)	0.73 (CI 0.40-1.36)	1.22 (CI 0.58-2.54)		
	aOR	0.79 (CI 0.47-1.31)	0.60 (CI 0.28-1.18)	1.43 (CI 0.58-3.52)		
Dyslipidemia	-	84/1923 (4.4%)	59/1397 (4.2%)	25/526 (4.8%)	1.13 (CI 0.70-1.83)	1.29 (CI 0.75-2.22)
	+	12/117 (10.3%)	7/67 (10.4%)	5/50 (10.0%)	0.95 (CI 0.28-3.20)	0.64 (CI 0.13-3.21)
	OR	2.50 (CI 1.33-4.73)	2.65 (CI 1.16-6.04)	2.23 (CI 0.81-6.10)		
	aOR	2.25 (CI 1.09-4.73)	3.07 (CI 1.26-7.50)	1.05 (CI 0.25-4.50)		
Proteinuria	-	86/1968 (4.4%)	62/1419 (4.4%)	24/549 (4.4%)	1.00 (CI 0.62-1.62)	1.04 (CI 0.60-1.79)
	+	10/26 (38.5%)	4/15 (26.7%)	6/11 (54.5%)	3.30 (CI 0.64-17.16)	11.69 (CI 0.61-225.96)
	OR	13.68 (CI 6.03-31.03)	7.96 (CI 2.46-25.70)	26.25 (CI 7.48-92.11)		
	aOR	12.64 (CI 4.37-36.54)	4.33 (CI 0.96-19.63)	56.85 (CI 9.02-358.46)		
≥ 2 constituents	-	73/1794 (4.1%)	54/1326 (4.1%)	19/468 (4.1%)	1.00 (CI 0.59-1.70)	-
	+	22/191 (11.5%)	11/103 (10.7%)	11/88 (12.5%)	1.20 (CI 0.49-2.91)	-
OR		3.07 (CI 1.86-5.07)	2.82 (CI 1.42-5.57)	3.38 (CI 1.55-7.37)		
II. <37 (n=169 (8.3%))		Total	113/1465 (7.7%)	56/576 (9.7%)	1.29 (CI 0.92-1.80)	1.45 (CI 0.99-2.12)
Hypertension	-	115/1682 (6.8%)	77/1216 (6.3%)	38/466 (8.2%)	1.31 (CI 0.88-1.97)	1.35 (CI 0.87-2.12)
	+	54/358 (15.1%)	36/249 (14.5%)	18/109 (16.5%)	1.17 (CI 0.63-2.17)	1.91 (CI 0.90-4.08)
	OR	2.42 (CI 1.71-3.42)	2.50 (CI 1.64-3.81)	2.23 (CI 1.22-4.08)		
	aOR	2.17 (CI 1.46-3.23)	2.13 (CI 1.31-3.47)	2.23 (CI 1.12-4.48)		
Obesity	-	118/1416 (8.3%)	88/1103 (8.0%)	30/313 (9.6%)	1.22 (CI 0.79-1.89)	1.66 (CI 1.03-2.67)
	+	50/618 (8.1%)	24/358 (6.7%)	26/260 (10.0%)	1.55 (CI 0.87-2.76)	1.27 (CI 0.68-2.38)
	OR	0.97 (CI 0.69-1.37)	0.83 (CI 0.52-1.32)	1.05 (CI 0.60-1.82)		
	aOR	0.99 (CI 0.68-1.44)	0.97 (CI 0.59-1.59)	0.81 (CI 0.42-1.54)		
Dyslipidemia	-	152/1923 (7.9%)	105/1397 (7.5%)	47/526 (8.9%)	1.21 (CI 0.84-1.73)	1.44 (CI 0.96-2.14)
	+	17/117 (14.5%)	8/67 (11.9%)	9/50 (18.0%)	1.62 (CI 0.58-4.55)	1.94 (CI 0.49-7.58)
	OR	1.98 (CI 1.15-3.40)	1.67 (CI 0.78-3.59)	2.24 (CI 1.02-4.89)		
	aOR	1.69 (CI 0.92-3.11)	1.61 (CI 0.70-3.67)	1.61 (CI 0.62-4.20)		
Proteinuria	-	154/1968 (7.8%)	104/1419 (7.3%)	50/549 (9.1%)	1.27 (CI 0.89-1.80)	1.39 (CI 0.94-2.04)
	+	10/26 (38.5%)	5/15 (33.3%)	5/11 (45.5%)	1.67 (CI 0.34-8.26)	5.11 (CI 0.24-108.70)
	OR	7.36 (CI 3.29-16.50)	6.32 (CI 2.12-18.84)	8.32 (CI 2.45-28.22)		
	aOR	4.72 (CI 1.67-13.35)	2.10 (CI 0.43-10.20)	14.41 (CI 2.57-80.78)		
≥ 2 constituents	-	136/1794 (7.6%)	96/1326 (7.2%)	40/468 (8.5%)	1.20 (CI 0.82-1.76)	-
	+	27/191 (19.4%)	12/103 (11.7%)	15/88 (17.0%)	1.56 (CI 0.69-3.54)	-
	OR	2.01 (CI 1.29-3.13)	1.69 (CI 0.89-3.19)	2.20 (CI 1.16-4.18)		
III. <34 (n=55 (2.7%))			GDM		OR	aOR
			-	+		
		Total	39/1465 (2.7%)	16/576 (2.8%)	1.05 (CI 0.58-1.89)	1.23 (CI 0.64-2.34)

Hypertension	-	33/1682 (2.0%)	25/1216 (2.1%)	8/466 (1.7%)	0.83 (CI 0.37-1.86)	0.99 (CI 0.43-2.29)
	+	22/358 (6.1%)	14/249 (5.6%)	8/109 (7.3%)	1.33 (CI 0.54-3.27)	1.74 (CI 0.56-5.47)
OR		3.27 (CI 1.88-5.68)	2.84 (CI 1.45-5.54)	4.54 (CI 1.66-12.37)		
aOR		2.96 (CI 1.59-5.53)	2.50 (CI 1.14-5.46)	4.05 (CI 1.35-12.19)		
Obesity	-	39/1416 (2.8%)	31/1103 (2.8%)	8/313 (2.6%)	0.91 (CI 0.41-1.99)	1.22 (CI 0.53-2.83)
	+	16/618 (2.6%)	8/358 (2.2%)	8/260 (3.1%)	1.39 (CI 0.51-3.75)	1.30 (CI 0.46-3.67)
OR		0.94 (CI 0.52-1.69)	0.79 (CI 0.36-1.74)	1.21 (CI 0.45-3.27)		
aOR		1.02 (CI 0.55-1.91)	0.98 (CI 0.43-2.24)	0.85 (CI 0.28-2.55)		
Dyslipidemia	-	49/1923 (2.5%)	36/1397 (2.6%)	13/526 (2.5%)	0.96 (CI 0.50-1.82)	1.21 (CI 0.61-2.40)
	+	6/117 (5.1%)	3/67 (4.5%)	3/50 (6.0%)	1.36 (CI 0.26-7.05)	1.36 (CI 0.09-20.47)
OR		2.07 (CI 0.87-4.93)	1.77 (CI 0.53-5.91)	2.52 (CI 0.69-9.15)		
aOR		1.90 (CI 0.76-4.76)	1.86 (0.54-6.42)	1.71 (CI 0.39-7.43)		
Proteinuria	-	48/1968 (2.4%)	33/1419 (2.3%)	15/549 (2.7%)	1.18 (CI 0.64-2.19)	1.24 (CI 0.64-2.40)
	+	5/26 (19.2%)	4/15 (26.7%)	1/11 (9.1%)	0.28 (CI 0.03-2.89)	NA
OR		9.52 (CI 3.45-26.32)	15.27 (CI 4.62-50.47)	3.56 (CI 0.43-29.62)		
aOR		5.16 (CI 1.33-20.08)	6.12 (CI 1.19-31.38)	3.62 (CI 0.29-45.45)		
≥ 2 constituents	-	40/1794 (2.2%)	30/1326 (2.3%)	10/468 (2.1%)	0.94 (CI 0.46-1.95)	-
	+	13/191 (6.8%)	7/103 (6.8%)	6/88 (6.8%)	1.00 (CI 0.32-3.11)	-
OR		3.20 (CI 1.68-6.10)	3.15 (CI 1.35-7.36)	3.35 (CI 1.19-9.47)		

Table S2. Odds ratios for the development of PE and delivery <37 weeks and <34 weeks. In vertical direction, ORs are calculated to explore the effect of the constituents for the group as a whole and sub-grouped without and with GDM. Along the horizontal axis, ORs are also detailed to explore an effect of GDM. Adjustments were made for the other constituents of the metabolic syndrome, age, Northern European ethnicity and gestational age at time of OGTT.